Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a young Indian boy with resistant alopecia areata who experienced nearly complete hair regrowth within 5 months of treatment with oral tofacitinib.

In this research, the authors reported that long-term treatment with the JAK1/JAK2 inhibitor baricitinib effectively maintains hair regrowth in patients with severe alopecia areata and may gradually improve outcomes for partial responders over 104 weeks, without increasing side effect incidence.

This study identified nine pathogenic variants in the PADI3 gene, and variants in the S100A3 and TCHH genes, which may disrupt protein function and contribute to central centrifugal cicatricial alopecia.

This study found that high TSPEAR expression in colorectal cancer was associated with poor prognosis and correlated with various tumor and immune-related factors.

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

In this study, genetic testing confirmed the diagnosis of Androgen insensitivity syndrome in most CAIS patients in Tunisia and identified two previously unreported mutations in the androgen receptor gene.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

This article introduces signatureSearch, a software package designed for gene expression signature searching and functional enrichment analysis, but reports no new clinical results.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

This study investigated dual TCR Treg cells in mouse tissues, revealing a high proportion and diverse pairing patterns compared to single TCR Tregs, providing insights into their origins and characteristics across different tissue locations.

Certain variations of the HDAC9 gene can increase or decrease stroke risk in the Chinese population.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

This study found that Musashi-2 regulates mRNA targets to restrict epithelial cell migration, revealing a key function of Msi2 beyond its known role in promoting cell growth.

This study found that introducing rat ornithine transcarbamylase gene into spf-ash mice improved liver and intestinal enzyme activity and normalized some metabolic indicators.

This study found that in mouse embryonic fibroblast cells lacking autophagy function, overexpression of Atg5 increased cell proliferation, while restoring autophagy reversed this effect, highlighting Atg5's dual role in tumorigenesis depending on autophagy conditions.

This article reviews the differences in inflammatory processes between alopecia universalis and atopic dermatitis, focusing on type 1 and type 2 immune responses, but it reports no new results.

This study found that nerve-mediated HDAC1 expression is necessary for blastema formation and limb regeneration in axolotls, and that inhibiting HDACs delays or inhibits this process.

This case study reports that tofacitinib effectively treated alopecia areata in a patient with Crohn's disease and maintained her Crohn's disease management.

In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.

Baricitinib helps with early hair regrowth in people with alopecia areata.

This study suggests a new subtype of alopecia, termed 'acute diffuse and total alopecia of the female scalp' (ADTAFS), characterized by acute and total hair loss in women with a favorable recovery profile.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

This study found that mouse and human protransglutaminase 3 enzymes require calcium-regulated activation for their role in later stages of cell envelope formation in the epidermis and hair follicle.

In this study, 40% of alopecia areata patients using topical 2% tofacitinib ointment achieved greater than 50% improvement in hair regrowth after six months, showing significant efficacy compared to controls, with no serious adverse effects reported.

This study identified four novel and one recurrent mutation in the AIRE gene among Arab families with APS1, suggesting these contribute to the disorder.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

This study highlights the role of immune dysregulation, microRNA modulation, and SIRT1 pathways in alopecia areata, suggesting antisense oligonucleotides targeting miR-485-3p as a promising therapeutic strategy for promoting hair regrowth and reducing inflammation in murine models.